• Active, not recruiting

NCT03236428: Phase 2: Phase II Study of the CD38 Antibody Daratumumab MGUS / Smoldering Myeloma SMM

Updated: May 23


NCT03236428: Phase 2: Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma


daratumumab

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma


This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM).


The drug involved in this study is:

-Daratumumab


Sponsor

Dana-Farber Cancer Institute


Collaborators

Janssen Pharmaceuticals

Multiple Myeloma Research Consortium

Blood Cancer Research Partnership

The Leukemia and Lymphoma Society


Information provided by (Responsible Party)

Irene Ghobrial, MD, Dana-Farber Cancer Institute

 

ClinicalTrials.gov Identifier: NCT03236428


Official Title: A Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

First Posted: August 1, 2017


Click here to see details on ClinicalTrials.gov

 

Drug: Daratumumab

 

Locations


United States, California

United States, Colorado

United States, Massachusetts

United States, Michigan






Posts Archive